Dr. Jeroen Tonnaer joined the company in 2015 to serve as Chief Business Officer, and is responsible for Cristal Therapeutics’ business development, partnering and licensing activities. Dr. Tonnaer has over 30 years of experience in drug discovery and development, research strategy, business development and licensing. He served in several leading positions at Organon and Schering-Plough, and was the business liaison for Schering-Plough in the public-private partnership Top Institute Pharma (TI Pharma). After Schering-Plough’s acquisition by Merck & Co (called MSD outside North America), Dr. Tonnaer headed MSD’s European External Scientific Affairs team, and was instrumental in the identification and execution of several major licensing and partnering deals with companies such as Ablynx, AiCuris and Delphi Genetics. Dr. Tonnaer holds an MSc degree in biology, a PhD in Pharmacology and is a Certified Licensing Professional (CLP™).
Business development and Management